

ASX Announcement/Press Release | 6 February 2025  
**AdAlta Limited (ASX:1AD)**

**Investor webinar invitation: “East to West” cellular immunotherapy strategy**

**AdAlta Limited (ASX:1AD) will host an investor webinar on Tuesday 11 February 2025.**

The webinar will be presented by AdAlta’s Chief Executive Officer & Managing Director, Dr Tim Oldham, and will be followed by a short Q&A session.

In his webinar presentation, Dr Oldham will discuss the results of AdAlta’s strategic review and portfolio prioritization announced separately today, including:

- What drives AdAlta’s “East to West” cellular immunotherapy strategy
- How the “East to West” strategy will be AdAlta’s key driver of future pipeline growth and value creation
- Recent progress made in executing the “East to West” strategy, including the signing of term sheets
- How the value inherent in AdAlta’s fibrosis disease drug candidate AD-214 will be monetised.

**AdAlta Investor Webinar Registration Details:**

**DATE:** Tuesday 11 February 2025

**TIME:** 12.00 noon AEDT

**FORMAT:** Zoom

**Please register in advance using the following link:**

[https://us02web.zoom.us/webinar/register/WN\\_RNWwB4MRRaeLxrjeb7ujOw](https://us02web.zoom.us/webinar/register/WN_RNWwB4MRRaeLxrjeb7ujOw)

After registering, you will receive a confirmation email containing information about joining the webinar.

**Reference Documents:**

- ASX announcement: “East to West” cellular immunotherapy strategy prioritized  
<https://investorhub.adalta.com.au/link/vPnple>

This ASX announcement has been authorised by the Board of AdAlta Limited.

**For further information, please contact:**

**AdAlta Limited (ASX:1AD)**

Tim Oldham  
CEO & Managing Director  
P: +61 3 9479 5159  
E: [t.oldham@adalta.com.au](mailto:t.oldham@adalta.com.au)

**Media & Investor Enquiries**

The Capital Network  
Julia Maguire  
P: +61 2 7257 7338  
E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

**About AdAlta**

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its 'East to West' strategy, the Company is integrating Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting 'Eastern' innovation in cellular immunotherapies with 'Western' regulated markets and patients.

AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.

AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US\$20.3 billion by 2028.

AdAlta's first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering.

To learn more, please visit: [www.adalta.com.au](http://www.adalta.com.au)

**For more information**



Join our [InvestorHub](#)



Follow us on [LinkedIn](#)



Follow us on [X \(formerly Twitter\)](#)